A citation-based method for searching scientific literature

Stephen B Hanauer, William J Sandborn, Paul Rutgeerts, Richard N Fedorak, Milan Lukas, Donald MacIntosh, Remo Panaccione, Douglas Wolf, Paul Pollack. Gastroenterology 2006
Times Cited: 1187







List of co-cited articles
1014 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
Jean-Frédéric Colombel, William J Sandborn, Paul Rutgeerts, Robert Enns, Stephen B Hanauer, Remo Panaccione, Stefan Schreiber, Dan Byczkowski, Ju Li, Jeffrey D Kent,[...]. Gastroenterology 2007
54

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
Stephen B Hanauer, Brian G Feagan, Gary R Lichtenstein, Lloyd F Mayer, S Schreiber, Jean Frederic Colombel, Daniel Rachmilewitz, Douglas C Wolf, Allan Olson, Weihang Bao,[...]. Lancet 2002
43

Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Brian G Feagan, William J Sandborn, Christopher Gasink, Douglas Jacobstein, Yinghua Lang, Joshua R Friedman, Marion A Blank, Jewel Johanns, Long-Long Gao, Ye Miao,[...]. N Engl J Med 2016
821
38

Vedolizumab as induction and maintenance therapy for Crohn's disease.
William J Sandborn, Brian G Feagan, Paul Rutgeerts, Stephen Hanauer, Jean-Frédéric Colombel, Bruce E Sands, Milan Lukas, Richard N Fedorak, Scott Lee, Brian Bressler,[...]. N Engl J Med 2013
37

Infliximab, azathioprine, or combination therapy for Crohn's disease.
Jean Frédéric Colombel, William J Sandborn, Walter Reinisch, Gerassimos J Mantzaris, Asher Kornbluth, Daniel Rachmilewitz, Simon Lichtiger, Geert D'Haens, Robert H Diamond, Delma L Broussard,[...]. N Engl J Med 2010
35

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
William J Sandborn, Paul Rutgeerts, Robert Enns, Stephen B Hanauer, Jean-Frédéric Colombel, Remo Panaccione, Geert D'Haens, Ju Li, Marie R Rosenfeld, Jeffrey D Kent,[...]. Ann Intern Med 2007
719
34

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
W J Sandborn, S B Hanauer, P Rutgeerts, R N Fedorak, M Lukas, D G MacIntosh, R Panaccione, D Wolf, J D Kent, B Bittle,[...]. Gut 2007
730
32

Infliximab maintenance therapy for fistulizing Crohn's disease.
Bruce E Sands, Frank H Anderson, Charles N Bernstein, William Y Chey, Brian G Feagan, Richard N Fedorak, Michael A Kamm, Joshua R Korzenik, Bret A Lashner, Jane E Onken,[...]. N Engl J Med 2004
27

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
S R Targan, S B Hanauer, S J van Deventer, L Mayer, D H Present, T Braakman, K L DeWoody, T F Schaible, P J Rutgeerts. N Engl J Med 1997
27

Certolizumab pegol for the treatment of Crohn's disease.
William J Sandborn, Brian G Feagan, Simeon Stoinov, Pieter J Honiball, Paul Rutgeerts, David Mason, Ralph Bloomfield, Stefan Schreiber. N Engl J Med 2007
779
26

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management.
Fernando Gomollón, Axel Dignass, Vito Annese, Herbert Tilg, Gert Van Assche, James O Lindsay, Laurent Peyrin-Biroulet, Garret J Cullen, Marco Daperno, Torsten Kucharzik,[...]. J Crohns Colitis 2017
24

Infliximab for induction and maintenance therapy for ulcerative colitis.
Paul Rutgeerts, William J Sandborn, Brian G Feagan, Walter Reinisch, Allan Olson, Jewel Johanns, Suzanne Travers, Daniel Rachmilewitz, Stephen B Hanauer, Gary R Lichtenstein,[...]. N Engl J Med 2005
22

Infliximab for the treatment of fistulas in patients with Crohn's disease.
D H Present, P Rutgeerts, S Targan, S B Hanauer, L Mayer, R A van Hogezand, D K Podolsky, B E Sands, T Braakman, K L DeWoody,[...]. N Engl J Med 1999
21

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Nicholas A Kennedy, Graham A Heap, Harry D Green, Benjamin Hamilton, Claire Bewshea, Gareth J Walker, Amanda Thomas, Rachel Nice, Mandy H Perry, Sonia Bouri,[...]. Lancet Gastroenterol Hepatol 2019
235
21

Maintenance therapy with certolizumab pegol for Crohn's disease.
Stefan Schreiber, Mani Khaliq-Kareemi, Ian C Lawrance, Ole Østergaard Thomsen, Stephen B Hanauer, Juliet McColm, Ralph Bloomfield, William J Sandborn. N Engl J Med 2007
733
20

ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment.
Joana Torres, Stefanos Bonovas, Glen Doherty, Torsten Kucharzik, Javier P Gisbert, Tim Raine, Michel Adamina, Alessandro Armuzzi, Oliver Bachmann, Palle Bager,[...]. J Crohns Colitis 2020
297
19

Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Brian G Feagan, Paul Rutgeerts, Bruce E Sands, Stephen Hanauer, Jean-Frédéric Colombel, William J Sandborn, Gert Van Assche, Jeffrey Axler, Hyo-Jong Kim, Silvio Danese,[...]. N Engl J Med 2013
17

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
William J Sandborn, Gert van Assche, Walter Reinisch, Jean-Frederic Colombel, Geert D'Haens, Douglas C Wolf, Martina Kron, Mary Beth Tighe, Andreas Lazar, Roopal B Thakkar. Gastroenterology 2012
782
16

Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
Niels Vande Casteele, Marc Ferrante, Gert Van Assche, Vera Ballet, Griet Compernolle, Kristel Van Steen, Steven Simoens, Paul Rutgeerts, Ann Gils, Séverine Vermeire. Gastroenterology 2015
566
16

Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
Paul Rutgeerts, Gert Van Assche, William J Sandborn, Douglas C Wolf, Karel Geboes, Jean-Frédéric Colombel, Walter Reinisch, Ashish Kumar, Andreas Lazar, Anne Camez,[...]. Gastroenterology 2012
408
16

Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
Bruce E Sands, Brian G Feagan, Paul Rutgeerts, Jean-Frédéric Colombel, William J Sandborn, Richmond Sy, Geert D'Haens, Shomron Ben-Horin, Jing Xu, Maria Rosario,[...]. Gastroenterology 2014
426
15

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
Walter Reinisch, William J Sandborn, Daniel W Hommes, Geert D'Haens, Stephen Hanauer, Stefan Schreiber, Remo Panaccione, Richard N Fedorak, Mary Beth Tighe, Bidan Huang,[...]. Gut 2011
574
14

ACG Clinical Guideline: Management of Crohn's Disease in Adults.
Gary R Lichtenstein, Edward V Loftus, Kim L Isaacs, Miguel D Regueiro, Lauren B Gerson, Bruce E Sands. Am J Gastroenterol 2018
483
14

Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
William J Sandborn, Christopher Gasink, Long-Long Gao, Marion A Blank, Jewel Johanns, Cynthia Guzzo, Bruce E Sands, Stephen B Hanauer, Stephan Targan, Paul Rutgeerts,[...]. N Engl J Med 2012
731
14

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
Geert D'Haens, Filip Baert, Gert van Assche, Philip Caenepeel, Philippe Vergauwe, Hans Tuynman, Martine De Vos, Sander van Deventer, Larry Stitt, Allan Donner,[...]. Lancet 2008
908
12

Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial.
Reena Khanna, Brian Bressler, Barrett G Levesque, Guangyong Zou, Larry W Stitt, Gordon R Greenberg, Remo Panaccione, Alain Bitton, Pierre Paré, Séverine Vermeire,[...]. Lancet 2015
273
12

Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis.
Glen S Hazlewood, Ali Rezaie, Meredith Borman, Remo Panaccione, Subrata Ghosh, Cynthia H Seow, Ellen Kuenzig, George Tomlinson, Corey A Siegel, Gil Y Melmed,[...]. Gastroenterology 2015
175
12

Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial.
William J Sandborn, Stefan Schreiber, Brian G Feagan, Paul Rutgeerts, Ziad H Younes, Ralph Bloomfield, Geoffroy Coteur, Juan Pablo Guzman, Geert R D'Haens. Clin Gastroenterol Hepatol 2011
110
11


Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
William J Sandborn, Chinyu Su, Bruce E Sands, Geert R D'Haens, Séverine Vermeire, Stefan Schreiber, Silvio Danese, Brian G Feagan, Walter Reinisch, Wojciech Niezychowski,[...]. N Engl J Med 2017
660
10

Crohn's disease.
Joana Torres, Saurabh Mehandru, Jean-Frédéric Colombel, Laurent Peyrin-Biroulet. Lancet 2017
780
10

Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
William J Sandborn, Brian G Feagan, Colleen Marano, Hongyan Zhang, Richard Strauss, Jewel Johanns, Omoniyi J Adedokun, Cynthia Guzzo, Jean-Frederic Colombel, Walter Reinisch,[...]. Gastroenterology 2014
460
10

American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease.
Joseph D Feuerstein, Geoffrey C Nguyen, Sonia S Kupfer, Yngve Falck-Ytter, Siddharth Singh. Gastroenterology 2017
295
10

Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Filip Baert, Maja Noman, Severine Vermeire, Gert Van Assche, Geert D' Haens, An Carbonez, Paul Rutgeerts. N Engl J Med 2003
10

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
William J Sandborn, Brian G Feagan, Richard N Fedorak, Ellen Scherl, Mark R Fleisher, Seymour Katz, Jewel Johanns, Marion Blank, Paul Rutgeerts. Gastroenterology 2008
553
10

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
P Rutgeerts, G D'Haens, S Targan, E Vasiliauskas, S B Hanauer, D H Present, L Mayer, R A Van Hogezand, T Braakman, K L DeWoody,[...]. Gastroenterology 1999
879
10

Adalimumab for the treatment of fistulas in patients with Crohn's disease.
J-F Colombel, D A Schwartz, W J Sandborn, M A Kamm, G D'Haens, P Rutgeerts, R Enns, R Panaccione, S Schreiber, J Li,[...]. Gut 2009
252
10

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Jean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, Milan Lukas, Filip Baert, Tomas Vaňásek, Ahmet Danalioglu, Gottfried Novacek, Alessandro Armuzzi, Xavier Hébuterne,[...]. Lancet 2017
409
9

Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease.
Konstantinos Karmiris, Gilles Paintaud, Maja Noman, Charlotte Magdelaine-Beuzelin, Marc Ferrante, Danielle Degenne, Karolien Claes, Tamara Coopman, Nele Van Schuerbeek, Gert Van Assche,[...]. Gastroenterology 2009
396
9

Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring.
Amit Assa, Manar Matar, Dan Turner, Efrat Broide, Batia Weiss, Oren Ledder, Anat Guz-Mark, Firas Rinawi, Shlomi Cohen, Chani Topf-Olivestone,[...]. Gastroenterology 2019
97
9


A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.
Stefan Schreiber, Paul Rutgeerts, Richard N Fedorak, Munaa Khaliq-Kareemi, Michael A Kamm, Michel Boivin, Charles N Bernstein, Michael Staun, Ole Østergaard Thomsen, Alison Innes. Gastroenterology 2005
426
9

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
L Peyrin-Biroulet, W Sandborn, B E Sands, W Reinisch, W Bemelman, R V Bryant, G D'Haens, I Dotan, M Dubinsky, B Feagan,[...]. Am J Gastroenterol 2015
9

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Bruce E Sands, Laurent Peyrin-Biroulet, Edward V Loftus, Silvio Danese, Jean-Frédéric Colombel, Murat Törüner, Laimas Jonaitis, Brihad Abhyankar, Jingjing Chen, Raquel Rogers,[...]. N Engl J Med 2019
231
9

Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis.
Uri Kopylov, Talal Al-Taweel, Mohammad Yaghoobi, Benedicte Nauche, Alain Bitton, Peter L Lakatos, Shomron Ben-Horin, Waqqas Afif, Ernest G Seidman. J Crohns Colitis 2014
67
13

Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.
Gary R Lichtenstein, Brian G Feagan, Russell D Cohen, Bruce A Salzberg, Robert H Diamond, Samiyeh Price, Wayne Langholff, Anil Londhe, William J Sandborn. Am J Gastroenterol 2012
496
9

Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
Pieter Dewint, Bettina E Hansen, Elke Verhey, Bas Oldenburg, Daniel W Hommes, Marieke Pierik, Cyriel I J Ponsioen, Hendrik M van Dullemen, Maurice Russel, Ad A van Bodegraven,[...]. Gut 2014
127
9

Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
Robert Battat, Uri Kopylov, Talat Bessissow, Alain Bitton, Albert Cohen, Anjali Jain, Myriam Martel, Ernest Seidman, Waqqas Afif. Clin Gastroenterol Hepatol 2017
132
8

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.
Geert D'Haens, Severine Vermeire, Guy Lambrecht, Filip Baert, Peter Bossuyt, Benjamin Pariente, Anthony Buisson, Yoram Bouhnik, Jérôme Filippi, Janneke Vander Woude,[...]. Gastroenterology 2018
159
8

Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.
Casper Steenholdt, Jørn Brynskov, Ole Østergaard Thomsen, Lars Kristian Munck, Jan Fallingborg, Lisbet Ambrosius Christensen, Gitte Pedersen, Jens Kjeldsen, Bent Ascanius Jacobsen, Anne Sophie Oxholm,[...]. Gut 2014
331
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.